Literature DB >> 10886275

Deep shave excision of macular melanocytic nevi with the razor blade biopsy technique.

T Gambichler1, E Senger, S Rapp, D Alamouti, P Altmeyer, K Hoffmann.   

Abstract

BACKGROUND: Shave excision is an established surgical method for removing benign skin lesions for cosmetic and functional reasons. Usually superficial shave excision is performed with a common scalpel blade for the removal of papular nevi. However, there is little known about deep shave excision of macular melanocytic nevi with the razor blade technique.
OBJECTIVE: The present study was undertaken to evaluate the cosmetic outcome of deep shave excision of macular melanocytic nevi with the razor blade technique. Moreover, its potency for sufficient removal of these lesions was investigated.
METHODS: Within routine skin cancer screening 45 outpatients with a total of 77 macular melanocytic nevi were prospectively recruited. Deep shave excisions of these lesions were performed with a double-edged razor blade followed by chemical hemostasis. Histologically all specimens were processed and evaluated in a routine manner. After 6 months the physician and patients evaluated the shave sites for cosmetic outcome with a score graded from 1 to 4 (1 = excellent; 2 = good; 3 = moderate; 4 = poor).
RESULTS: Histologically 88% (68 of 77) of the melanocytic lesions were described as completely excised and 60% (46 of 77) were diagnosed as atypical melanocytic nevi; 12% (9 of 77) of the nevi were incompletely excised on the depth. On average, the deep margin of the specimens (n = 77) was 0.5 mm (range 0-1.8 mm) and the lateral margin was 2 mm (range 0.3-8.2 mm). After 6 months 56 shave sites could be reassessed. We observed mild hypopigmentation in 52% (29 of 56), hyperpigmentation in 32% (18 of 56), and erythema in 23% (13 of 56). Recurrent nevi occurred in 13% (7 of 56). The evaluation of the cosmetic outcome by the patients (mean score 1.7) achieved better results than the evaluation by the physician (mean score 2.5). The cosmetic results showed no significant (P >.05) differences in various anatomic sites.
CONCLUSION: Our data confirm that deep razor blade excision presents a highly useful and inexpensive method for the removal of macular melanocytic nevi that yields adequate specimens for pathologic interpretation. We consider that shave excision with the razor blade technique is potentially much less scarring than full-thickness scalpel excisions of nevi. In particular, this is of great significance for patients with multiple nevi, such as dysplastic nevi syndrome.

Entities:  

Mesh:

Year:  2000        PMID: 10886275     DOI: 10.1046/j.1524-4725.2000.00036.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  5 in total

1.  United States Preventive Services Task Force Overstates Cosmetic Harms of Skin Cancer Screening.

Authors:  Joseph F Sobanko; Kimberly Shao; Rebecca L Pearl; Sancy Leachman
Journal:  J Clin Aesthet Dermatol       Date:  2018-04-01

2.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-12-16       Impact factor: 11.527

3.  Serial excision of congenital melanocytic nevi.

Authors:  Vinod K Jain; Mahendra K Singhi; Rajiv Goyal
Journal:  J Cutan Aesthet Surg       Date:  2008-01

Review 4.  Optimal management of common acquired melanocytic nevi (moles): current perspectives.

Authors:  Kabir Sardana; Payal Chakravarty; Khushbu Goel
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-03-19

Review 5.  Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Authors:  Mariah M Johnson; Sancy A Leachman; Lisa G Aspinwall; Lee D Cranmer; Clara Curiel-Lewandrowski; Vernon K Sondak; Clara E Stemwedel; Susan M Swetter; John Vetto; Tawnya Bowles; Robert P Dellavalle; Larisa J Geskin; Douglas Grossman; Kenneth F Grossmann; Jason E Hawkes; Joanne M Jeter; Caroline C Kim; John M Kirkwood; Aaron R Mangold; Frank Meyskens; Michael E Ming; Kelly C Nelson; Michael Piepkorn; Brian P Pollack; June K Robinson; Arthur J Sober; Shannon Trotter; Suraj S Venna; Sanjiv Agarwala; Rhoda Alani; Bruce Averbook; Anna Bar; Mirna Becevic; Neil Box; William E Carson; Pamela B Cassidy; Suephy C Chen; Emily Y Chu; Darrel L Ellis; Laura K Ferris; David E Fisher; Kari Kendra; David H Lawson; Philip D Leming; Kim A Margolin; Svetomir Markovic; Mary C Martini; Debbie Miller; Debjani Sahni; William H Sharfman; Jennifer Stein; Alexander J Stratigos; Ahmad Tarhini; Matthew H Taylor; Oliver J Wisco; Michael K Wong
Journal:  Melanoma Manag       Date:  2017-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.